US$ 28.47
glp-1 agonist dpp 4 inhibitor DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits dpp-4_inhibitors [TUSOM | Pharmwiki]
Description
All groups showed a decrease in mean HbA1c by week 12, with higher doses of LY demonstrating statistically significant placebo-adjusted decreases of up to 1.56%
![glp-1 agonist dpp 4 inhibitor DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits dpp-4_inhibitors [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/dpp4.png?w=600&tok=f9724b)
No adverse effects were observed in the breastfed babies involved in the study
![glp-1 agonist dpp 4 inhibitor DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits dpp-4_inhibitors [TUSOM | Pharmwiki]](https://www.ijpsjournal.com/uploads/article_images/art_4200_aca82f11a05f1a9e246a35653b3cb204.jpeg)
Real-world results vary based on dose, adherence, diet, activity level, and individual biology
![glp-1 agonist dpp 4 inhibitor DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits dpp-4_inhibitors [TUSOM | Pharmwiki]](https://i.ytimg.com/vi/YRCELHdfGFI/mqdefault.jpg)
Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study
![glp-1 agonist dpp 4 inhibitor DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits dpp-4_inhibitors [TUSOM | Pharmwiki]](https://www.mdpi.com/molecules/molecules-27-03055/article_deploy/html/images/molecules-27-03055-g001-550.jpg)
JNMA J Nepal Med Assoc 2022
![glp-1 agonist dpp 4 inhibitor DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits dpp-4_inhibitors [TUSOM | Pharmwiki]](https://www.researchgate.net/publication/357859778/figure/fig8/AS:1127927353753611@1645930245485/Inhibition-of-DPP-4-Food-consumption-boosts-the-release-of-GLP-1-and-GIP-blue-and-red.png)